PMID- 32925829
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 1473-5628 (Electronic)
IS  - 0143-3636 (Linking)
VI  - 41
IP  - 12
DP  - 2020 Dec
TI  - Preliminary evaluation of 18F-FDG-PET/MRI for differentiation of serous from 
      nonserous pancreatic cystic neoplasms: a pilot study.
PG  - 1257-1264
LID - 10.1097/MNM.0000000000001277 [doi]
AB  - OBJECTIVES: The aim of the study was to evaluate preliminary feasibility of 
      18F-FDG-PET/MRI in differentiation of pancreatic serous cystic neoplasms (SCNs) 
      from non-SCNs. METHODS: From August 2017 to June 2019, 10 patients (3 men, 7 
      women; mean age, 63 years) previously diagnosed with pancreatic cystic neoplasm 
      underwent simultaneous 18F-FDG-PET/MRI prospectively on an integrated 3-Tesla 
      hybrid PET/MRI scanner. PET images were analyzed visually and semiquantitatively 
      measuring standardized uptake values (SUV) including lesion SUVmax and SUVmean, 
      lesion to pancreas and lesion to liver SUVmax and SUVmean ratio independent of 
      MRI diagnosis. The reference standard for lesion diagnosis was by MRI features 
      and interval follow-up. RESULTS: Visual assessment of PET images demonstrated 
      uptake in 57% of SCNs. Lesion to liver SUVmax ratio of >/=0.5 showed the highest 
      accuracy (90%) and area under the curve (0.9) followed by lesion SUVmax of >/=1.6 
      and lesion to pancreas SUVmax ratio of >/=0.77 for diagnosis of SCN. The 
      sensitivity for lesion SUVmax of >/=1.6 was less than two other ones (71 versus 
      100%). All non-SCNs exhibited SUVmax value less than 1.6 while 33 and 66% 
      demonstrated lesion to liver SUVmax ratio of >0.5 and lesion to pancreas SUVmax 
      ratio of >0.77, respectively. PET/MRI specificity was 67, 100, 67 and 33% through 
      lesion to liver SUVmax ratio, lesion SUVmax, lesion SUVmean and lesion to 
      pancreas SUVmax ratio, respectively, for diagnosis of SCN. CONCLUSION: 
      Preliminary results show that PET/MRI utilization is promising for 
      differentiation of pancreatic SCN from non-SCN lesions. This could reduce need 
      for surveillance imaging or avoidance of unnecessary intervention in pancreatic 
      cystic neoplasms with uncertain diagnoses.
FAU - Sagheb, Soodeh
AU  - Sagheb S
AD  - Joint Department of Medical Imaging.
FAU - Metser, Ur
AU  - Metser U
AD  - Joint Department of Medical Imaging, University Health Network, Mount Sinai 
      Hospital, Women's College Hospital.
FAU - Razaz, Suzan
AU  - Razaz S
AD  - Department of Medical Imaging.
FAU - Menezes, Ravi
AU  - Menezes R
AD  - Joint Department of Medical Imaging.
FAU - Gallinger, Steven
AU  - Gallinger S
AD  - Department of Surgery, University Health Network, University of Toronto, Toronto, 
      Ontario, Canada.
FAU - Jhaveri, Kartik S
AU  - Jhaveri KS
AD  - Joint Department of Medical Imaging, University Health Network, Mount Sinai 
      Hospital, Women's College Hospital.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nucl Med Commun
JT  - Nuclear medicine communications
JID - 8201017
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Diagnosis, Differential
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - *Multimodal Imaging
MH  - Pancreatic Neoplasms/*diagnostic imaging/*pathology
MH  - Pilot Projects
MH  - *Positron-Emission Tomography
EDAT- 2020/09/15 06:00
MHDA- 2021/08/04 06:00
CRDT- 2020/09/14 15:45
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
PHST- 2020/09/14 15:45 [entrez]
AID - 00006231-202012000-00006 [pii]
AID - 10.1097/MNM.0000000000001277 [doi]
PST - ppublish
SO  - Nucl Med Commun. 2020 Dec;41(12):1257-1264. doi: 10.1097/MNM.0000000000001277.